Epilog can de-risk clinical trials

EEG biomarkers, objective patient selection and standardized reporting

The problem

Lack of objective parameters

  1. Most clinical trials use subjective measures as inclusion criteria as well as outcomes
  2. This significantly increases the risk of failure in phase 2 & 3 trials, leading to promising molecules not making it to clinical application
The opportunity

Using EEG as a window to the brain

  1. A direct measure of electrical brain activity
  2. With high frequency sampling that enables capturing fast brain dynamics
  3. Measuring across the entire convexity to elucidate global brain networks
Pic courtesy: www.zetoinc.com/

Under the impulse of technical innovations, EEG is undergoing a strong renaissance.

  1. Recording is made easier by the use of new devices, enabling e.g. home monitoring
  2. Increased computation power, the use of cloud-based solutions and more extensive validation of methods makes it possible to provide assistance in EEG interpretation
The Solution

Our toolbox

Spike-Q
Spike count and localisation, e.g. spike-wave index
Spectral-Q
Quantification of brain rhythms in the different frequency bands.
NET-Q
Elucidates brain networks through functional connectivity analysis.

Examples of potential benefits in # phases of development

Pre-Clinical

– Standardized reporting
– Data centralization
– Increased sensitivity to pick-up signals

Phase 2

– Standardized reporting
– Data centralization
– Control type of epilepsy for homogenous population
– Non-clinical seizures
– Responder / non-responder

Phase 3

– Standardized reporting
– Data centralization
– Ensure homogenous population
– Non-clinical seizures
– Patient stratification

Phase 4

– Standardized RWE
– Data centralization
– Impact on sleep
– Retrospective analysis